
Emcure Pharmaceuticals Approved C.S. Muralidharan’s Appointment As Independent Director
C.S. Muralidharan has been appointed as an Independent Director of Emcure Pharmaceuticals Limited, with effect from April 1, 2026. The appointment was approved on April 27, 2026, by way of Postal Ballot through a remote e-voting process.
Muralidharan served as Group Chief Financial Officer (CFO) at Sun Pharmaceutical Industries, where he was involved in financial management and corporate strategy. During his career, he has worked with organisations including Indian Oil Corporation Ltd., Ranbaxy Laboratories, Lupin Ltd., Matrix Laboratories, and Watson Pharmaceuticals. He is a finance and strategy professional with over four decades of experience across the hydrocarbon and pharmaceutical sectors. Muralidharan is a Cost and Management Accountant and has completed the Executive Programme in General Management from the University Of Chicago Booth School Of Business. His work has spanned areas such as mergers and acquisitions (M&A), enterprise risk management, and environmental, social, and governance (ESG) initiatives.




